Status:
COMPLETED
Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination
Lead Sponsor:
Seoul National University Bundang Hospital
Conditions:
Diabetes
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
It is well established that inhibition of dipeptidyl peptidase (DPP)-IV reduces glucose levels in both fasting and postprandial states and preserves pancreatic beta cell function in patients with type...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- HbA1c ≥ 7%
- Age ≥ 18
Exclusion
- Contraindication to sitagliptin or metformin
- Pregnant or breast feeding women
- Reproductive-age women who refuse contraception
- Type 1 diabetes, gestational diabetes, or diabetes with secondary cause
- Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT \> 3-fold the upper limit of normal)
- Renal failure (Cr \> 2.0)
- Cancer within 5 years (except squamous cell cancer, cervical cancer, thyroid cancer with appropriate treatment)
- Not appropriate for oral antidiabetic agent
- Medication which affect glycemic control
- Disease which affect efficacy and safety of drugs
- Other clinical trial within 30 days
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00969566
Start Date
January 1 2009
End Date
July 1 2011
Last Update
January 6 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 463-707